Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hydroxychloroquine + valsartan
- Development stage
- Phase 4
- Lead developer
- Peking Union Medical College Hospital
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Hydroxychloroquine + valsartan is a combination therapy investigated for the treatment of primary IgA nephropathy (IgAN). Hydroxychloroquine is an antimalarial and immunomodulatory small molecule that reduces immune activation by inhibiting Toll-like receptor 9 (TLR9) signaling and the subsequent production of inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-alpha (IFN-α). Valsartan is an angiotensin II receptor blocker (ARB) that provides renoprotection by antagonizing the angiotensin II type 1 (AT1) receptor, leading to reduced blood pressure and decreased proteinuria. This combination was specifically evaluated by the Peking Union Medical College Hospital in the HCQIgAN trial to address persistent proteinuria in IgAN patients who have an inadequate response to standard ARB therapy alone.
- Other names
- hydroxychloroquine sulfate + valsartan
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)DNAIFN-α (Interferon alpha-7)IL-6 (Interleukin 6)TLR9 (Toll-like receptor 9)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on hydroxychloroquine + valsartan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hydroxychloroquine + valsartan.